Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo (lenacapavir), a new era of HIV prevention has dawned. The approval, which ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...